{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:52:10Z","timestamp":1760403130087,"version":"build-2065373602"},"reference-count":65,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["17\/601"],"award-info":[{"award-number":["17\/601"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>High-dose human recombinant erythropoietin (rEPO) is a promising potential neuroprotective treatment in preterm and full-term neonates with hypoxic-ischemic encephalopathy (HIE). There are limited data on the pharmacokinetics of high-dose rEPO in neonates. We examined the effects of body weight, gestation age, global asphyxia, cerebral ischemia, hypothermia and exogenous rEPO on the pharmacokinetics of high-dose rEPO in fetal sheep. Near-term fetal sheep on gestation day 129 (0.87 gestation) (full term 147 days) received sham-ischemia (n = 5) or cerebral ischemia for 30 min followed by treatment with vehicle (n = 4), rEPO (n = 8) or combined treatment with rEPO and hypothermia (n = 8). Preterm fetal sheep on gestation day 104 (0.7 gestation) received sham-asphyxia (n = 1) or complete umbilical cord occlusion for 25 min followed by i.v. infusion of vehicle (n = 8) or rEPO (n = 27) treatment. rEPO was given as a loading bolus, followed by a prolonged continuous infusion for 66 to 71.5 h in preterm and near-term fetuses. A further group of preterm fetal sheep received repeated bolus injections of rEPO (n = 8). The plasma concentrations of rEPO were best described by a pharmacokinetic model that included first-order and mixed-order elimination with linear maturation of elimination with gestation age. There were no detectable effects of therapeutic hypothermia, cerebral ischemia, global asphyxia or exogenous treatment on rEPO pharmacokinetics. The increase in rEPO elimination with gestation age suggests that to maintain target exposure levels during prolonged treatment, the dose of rEPO may have to be adjusted to match the increase in size and growth. These results are important for designing and understanding future studies of neuroprotection with high-dose rEPO.<\/jats:p>","DOI":"10.3390\/ijms21093042","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T05:05:32Z","timestamp":1588050332000},"page":"3042","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Effect of Size, Maturation, Global Asphyxia, Cerebral Ischemia, and Therapeutic Hypothermia on the Pharmacokinetics of High-Dose Recombinant Erythropoietin in Fetal Sheep"],"prefix":"10.3390","volume":"21","author":[{"given":"Simerdeep K.","family":"Dhillon","sequence":"first","affiliation":[{"name":"The Department of Physiology, The University of Auckland, Auckland 1023, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Wassink","sequence":"additional","affiliation":[{"name":"The Department of Physiology, The University of Auckland, Auckland 1023, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8937-0846","authenticated-orcid":false,"given":"Christopher A.","family":"Lear","sequence":"additional","affiliation":[{"name":"The Department of Physiology, The University of Auckland, Auckland 1023, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne O.","family":"Davidson","sequence":"additional","affiliation":[{"name":"The Department of Physiology, The University of Auckland, Auckland 1023, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4031-2514","authenticated-orcid":false,"given":"Nicholas H.G.","family":"Holford","sequence":"additional","affiliation":[{"name":"The Department of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland 1023, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-7035","authenticated-orcid":false,"given":"Alistair J.","family":"Gunn","sequence":"additional","affiliation":[{"name":"The Department of Physiology, The University of Auckland, Auckland 1023, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bennet","sequence":"additional","affiliation":[{"name":"The Department of Physiology, The University of Auckland, Auckland 1023, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"key":"ref_1","first-page":"CD004863","article-title":"Early erythropoietin for preventing red blood cell transfusion in preterm and\/or low birth weight infants","volume":"4","author":"Ohlsson","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000486820","article-title":"High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL): A Randomized Controlled Trial\u2014Background, Aims, and Study Protocol","volume":"113","author":"Juul","year":"2018","journal-title":"Neonatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1515\/jpm-2018-0360","article-title":"Erythropoietin in perinatal hypoxic-ischemic encephalopathy: A systematic review and meta-analysis","volume":"47","author":"Razak","year":"2019","journal-title":"J. Perinat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e20160191","DOI":"10.1542\/peds.2016-0191","article-title":"High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: A phase II trial","volume":"137","author":"Wu","year":"2016","journal-title":"Pediatrics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2017.12.010","article-title":"Neonatal erythropoietin mitigates impaired gait, social interaction and diffusion tensor imaging abnormalities in a rat model of prenatal brain injury","volume":"302","author":"Robinson","year":"2018","journal-title":"Exp. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/cercor\/bhu066","article-title":"Postnatal Erythropoietin Mitigates Impaired Cerebral Cortical Development Following Subplate Loss from Prenatal Hypoxia-Ischemia","volume":"25","author":"Jantzie","year":"2015","journal-title":"Cereb. Cortex"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1113\/JP279131","article-title":"Non-additive effects of adjunct erythropoietin therapy with therapeutic hypothermia after global cerebral ischaemia in near-term fetal sheep","volume":"598","author":"Wassink","year":"2020","journal-title":"J. Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Oorschot, D.E., Sizemore, R.J., and Amer, A.R. (2020). Treatment of Neonatal Hypoxic-Ischemic Encephalopathy with Erythropoietin Alone, and Erythropoietin Combined with Hypothermia: History, Current Status, and Future Research. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041487"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1907423","article-title":"A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants","volume":"382","author":"Juul","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1203\/pdr.0b013e3180332cec","article-title":"A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats","volume":"61","author":"Kellert","year":"2007","journal-title":"Pediatr. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1203\/pdr.0b013e31805341dc","article-title":"Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats","volume":"61","author":"Statler","year":"2007","journal-title":"Pediatr. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1542\/peds.2007-2711","article-title":"A phase I\/II trial of high-dose erythropoietin in extremely low birth weight infants: Pharmacokinetics and safety","volume":"122","author":"Juul","year":"2008","journal-title":"Pediatrics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/pr.2017.15","article-title":"High-dose erythropoietin population pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia","volume":"81","author":"Frymoyer","year":"2017","journal-title":"Pediatr. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1542\/peds.2012-0498","article-title":"Erythropoietin for neuroprotection in neonatal encephalopathy: Safety and pharmacokinetics","volume":"130","author":"Wu","year":"2012","journal-title":"Pediatrics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1135","DOI":"10.1542\/peds.2009-2268","article-title":"Human recombinant erythropoietin in asphyxia neonatorum: Pilot trial","volume":"125","author":"Elmahdy","year":"2010","journal-title":"Pediatrics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3109\/14767058.2013.855894","article-title":"Single dose recombinant erythropoietin versus moderate hypothermia for neonatal hypoxic ischemic encephalopathy in low resource settings","volume":"27","author":"Awad","year":"2014","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1001\/jama.2016.5504","article-title":"Neuroprotection Trial Group. Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial","volume":"315","author":"Natalucci","year":"2016","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jcph.1368","article-title":"A mechanism-based population pharmacokinetics model of erythropoietin in premature infants and healthy adults following multiple intravenous doses","volume":"59","author":"Widness","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1177\/0271678X16650455","article-title":"Partial white and grey matter protection with prolonged infusion of recombinant human erythropoietin after asphyxia in preterm fetal sheep","volume":"37","author":"Wassink","year":"2017","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1177\/0271678X18791631","article-title":"Limited benefit of slow rewarming after cerebral hypothermia for global cerebral ischemia in near-term fetal sheep","volume":"39","author":"Davidson","year":"2019","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1113\/JP275627","article-title":"Time and sex dependent effects of magnesium sulphate on post-asphyxial seizures in preterm fetal sheep","volume":"596","author":"Bennet","year":"2018","journal-title":"J. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1113\/JP275434","article-title":"Evolving changes in fetal heart rate variability and brain injury after hypoxia-ischaemia in preterm fetal sheep","volume":"596","author":"Yamaguchi","year":"2018","journal-title":"J. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105013","DOI":"10.1016\/j.ejps.2019.105013","article-title":"Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens","volume":"138","author":"Schmidt","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00431-006-0189-x","article-title":"Population clinical pharmacology of children: Modelling covariate effects","volume":"165","author":"Anderson","year":"2006","journal-title":"Eur. J. Pediatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00431-006-0188-y","article-title":"Population clinical pharmacology of children: General principles","volume":"165","author":"Anderson","year":"2006","journal-title":"Eur. J. Pediatr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.ejps.2017.05.056","article-title":"Allometric size: The scientific theory and extension to normal fat mass","volume":"109s","author":"Holford","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","article-title":"A size standard for pharmacokinetics","volume":"30","author":"Holford","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A pharmacokinetic standard for babies and adults","volume":"102","author":"Holford","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2018.02.001","article-title":"Does poor fetal growth influence the extent of fetal exposure to maternal medications?","volume":"130","author":"Soo","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2165\/00003088-200241120-00003","article-title":"Ontogeny of hepatic and renal systemic clearance pathways in infants: Part I","volume":"41","author":"Alcorn","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00467-005-2105-4","article-title":"Ontogeny of drug elimination by the human kidney","volume":"21","author":"Chen","year":"2006","journal-title":"Pediatr. Nephrol."},{"key":"ref_32","first-page":"1205","article-title":"In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep","volume":"279","author":"Widness","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_33","first-page":"227","article-title":"Pharmacokinetics of recombinant human erythropoietin in rabbits and 3\/4 nephrectomized rats","volume":"96","author":"Yoon","year":"1997","journal-title":"Res. Commun. Mol. Pathol. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1600-0609.1995.tb01777.x","article-title":"The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers","volume":"54","author":"Jensen","year":"1995","journal-title":"Eur. J. Haematol."},{"key":"ref_35","first-page":"520","article-title":"Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats","volume":"283","author":"Kato","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood-2004-03-1216","article-title":"Both proteasomes and lysosomes degrade the activated erythropoietin receptor","volume":"105","author":"Walrafen","year":"2005","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10928-007-9074-0","article-title":"Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO)","volume":"34","author":"Woo","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_38","first-page":"820","article-title":"Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: Evidence for bone marrow as a major erythropoietin elimination pathway","volume":"298","author":"Chapel","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1124\/jpet.109.163568","article-title":"Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia","volume":"333","author":"Nalbant","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0378-3782(98)00030-9","article-title":"Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus","volume":"52","author":"Juul","year":"1998","journal-title":"Early Hum. Dev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0303-7207(01)00718-3","article-title":"Quantitation of the mRNA levels of Epo and EpoR in various tissues in the ovine fetus","volume":"188","author":"David","year":"2002","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/00007611-198207000-00017","article-title":"Effect of asphyxia on theophylline clearance in newborns","volume":"75","author":"Gal","year":"1982","journal-title":"South. Med. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000457157","article-title":"The influence of asphyxia on phenobarbital dosing requirements in neonates","volume":"7","author":"Gal","year":"1984","journal-title":"Dev. Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.brainres.2004.06.057","article-title":"Hypoxia-ischemia affects erythropoietin and erythropoietin receptor expression pattern in the neonatal rat brain","volume":"1021","author":"Spandou","year":"2004","journal-title":"Brain Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3171\/2010.5.PEDS1032","article-title":"Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxic-ischemic injury","volume":"6","author":"Mazur","year":"2010","journal-title":"J. Neurosurg. Pediatr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000085995","article-title":"Expression of erythropoietin and its receptor in the brain of late-gestation fetal sheep, and responses to asphyxia caused by umbilical cord occlusion","volume":"27","author":"Yan","year":"2005","journal-title":"Dev. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/17425255.2011.574127","article-title":"The effect of therapeutic hypothermia on drug metabolism and response: Cellular mechanisms to organ function","volume":"7","author":"Zhou","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"F335","DOI":"10.1136\/fetalneonatal-2011-300964","article-title":"Distribution and severity of hypoxic-ischaemic lesions on brain MRI following therapeutic cooling: Selective head versus whole body cooling","volume":"97","author":"Sarkar","year":"2012","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/STROKEAHA.109.570325","article-title":"Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic\/ischemic brain injury","volume":"41","author":"Iwai","year":"2010","journal-title":"Stroke"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11010-016-2779-x","article-title":"Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts","volume":"421","author":"Hermanowicz","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/bdd.757","article-title":"Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep","volume":"32","author":"Schmidt","year":"2011","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_52","first-page":"R1829","article-title":"Developmental regulation of erythropoietin and erythropoiesis","volume":"273","author":"Moritz","year":"1997","journal-title":"Am. J. Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.clp.2019.02.014","article-title":"Principles of Pharmacokinetics in the Pregnant Woman and Fetus","volume":"46","author":"Ward","year":"2019","journal-title":"Clin. Perinatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1203\/00006450-198906000-00019","article-title":"Impermeability of the ovine placenta to 35S-recombinant erythropoietin","volume":"25","author":"Widness","year":"1989","journal-title":"Pediatr. Res."},{"key":"ref_55","first-page":"139","article-title":"Lack of maternal to fetal transfer of 125I-labelled erythropoietin in sheep","volume":"15","author":"Widness","year":"1991","journal-title":"J. Dev. Physiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/bjh.16233","article-title":"Management of anaemia in pre-term infants","volume":"188","author":"Flanagan","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kilkenny, C., Browne, W.J., Cuthill, I.C., Emerson, M., and Altman, D.G. (2010). Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol., 8.","DOI":"10.1371\/journal.pbio.1000412"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000074970","article-title":"Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin","volume":"85","author":"Juul","year":"2004","journal-title":"Biol. Neonate"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1020561807903","article-title":"Assumption testing in population pharmacokinetic models: Illustrated with an analysis of moxonidine data from congestive heart failure patients","volume":"26","author":"Karlsson","year":"1998","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"ref_60","unstructured":"Bauer, R.J., Boeckmann, A., Beal, S., and Sheiner, L.B. (2019). NONMEM User\u2019s Guides. (1989\u20132019), Icon Development Solutions."},{"key":"ref_61","unstructured":"Holford, N.H.G. (2019, February 13). Wings for NONMEM Version 742 for NONMEM 7.4, 7.3 and 7.2. Available online: http:\/\/wfn.sourceforge.net."},{"key":"ref_62","unstructured":"Holford, N.H.G. (2019, February 13). Available online: www.page-meeting.org\/?abstract=738."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","article-title":"A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models","volume":"59","author":"Parke","year":"1999","journal-title":"Comput. Methods Programs Biomed."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10928-013-9343-z","article-title":"Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: A simulation study in population pharmacokinetics","volume":"41","author":"Thai","year":"2014","journal-title":"J. Pharmacokinet. Pharmacodyn."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3042\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:38:31Z","timestamp":1760366311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["ijms21093042"],"URL":"https:\/\/doi.org\/10.3390\/ijms21093042","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2020,4,25]]}}}